Manuela da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manuela da Silva has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
- Amber Hartman Scholz
Leibniz Institute DSMZ German Collection of Microorganisms and Cell Cultures , Inhoffenstraße 7B, Braunschweig 38124
3 shared publications Elisa Esposito
3 shared publications- Katharine Barker
National Museum of Natural History, Smithsonian Institution, Washington, DC 20560, USA
3 shared publications - Lara Durães Sette
Instituto de Biociências, Universidade Estadual Paulista (UNESP), Rio Claro 13506-900, SP, Brazil
3 shared publications Vanderlei P. Canhos
3 shared publicationsAlexandre da Silva de França
Biocatalysis Laboratory, National Institute of Technology (INT), Ministry of Science, Technology, Innovation and Communication (MCTIC), Rio de Janeiro, Brazil
2 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Oxford University Press (OUP) in BioScience
Connecting biodiversity biobanks in the global infrastructure landscape
The Global Genome Biodiversity Network (GGBN) is an international consortium of biodiversity biobanks and collections that strives to standardize and exchange best practices, and to share information on molecular biodiversity resources held in repositories around the globe. GGBN’s goal is to bridge the gap between biological material stored in these biobanks and the broader research community by establishing a searchable index of the world’s genomic resources, openly available to the scientific community and all stakeholders. Here, we provide examples of how GGBN interacts synergistically with other biodiversity programs and initiatives to (1) connect researchers with physical materials linked to rich, highly structured contextual metadata and (2) strengthen the biobanking community.
- 23 September 2026
- Published by Oxford University Press (OUP) in BioScience
Open AccessConnecting biodiversity biobanks in the global infrastructure landscape
The Global Genome Biodiversity Network (GGBN) is an international consortium of biodiversity biobanks and collections that strives to standardize and exchange best practices, and to share information on molecular biodiversity resources held in repositories around the globe. GGBN’s goal is to bridge the gap between biological material stored in these biobanks and the broader research community by establishing a searchable index of the world’s genomic resources, openly available to the scientific community and all stakeholders. Here, we provide examples of how GGBN interacts synergistically with other biodiversity programs and initiatives to (1) connect researchers with physical materials linked to rich, highly structured contextual metadata and (2) strengthen the biobanking community.
- 26 February 2026
- Published by Elsevier in Trends in Microbiology
- Vol. 34 (3) , 232-234
Addressing gaps: Brazil’s approach to microbial biobanks
- 26 February 2026
- Published by Elsevier in Trends in Microbiology
- Vol. 34 (3) , 232-234
Addressing gaps: Brazil’s approach to microbial biobanks
- Open Access
- 9 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-8
Harmonize rules for digital sequence information benefit-sharing across UN frameworks
As multiple UN fora develop parallel rules for sharing benefits from digital sequence information, we urge better coordination. International policymakers should focus on harmonizing new benefit-sharing rules to ensure open access to data, database interoperability, and better benefit sharing outcomes.
- 9 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-8
Open AccessHarmonize rules for digital sequence information benefit-sharing across UN frameworks
As multiple UN fora develop parallel rules for sharing benefits from digital sequence information, we urge better coordination. International policymakers should focus on harmonizing new benefit-sharing rules to ensure open access to data, database interoperability, and better benefit sharing outcomes.
- Open Access
- 26 June 2024
- Published by Frontiers Media SA in Frontiers in Tropical Diseases
- Vol. 5, 1420326
Challenges of the new Fiocruz Biodiversity and Health Biobank for preparedness and response to emerging and re-emerging infectious diseases
During the COVID-19 pandemic, the Oswaldo Cruz Foundation (Fiocruz), a Brazilian federal research institution supported by the Brazilian Health Ministry, established a biobank. This biobank began by preserving the SARS-CoV-2 virus and human biological material related to COVID-19. This innovative initiative combined human and biodiversity materials within a single infrastructure. Designed for supporting research, development, and innovation in healthcare and preparedness and response to emerging and re-emerging infectious diseases, the biobank’s focus has since expanded to include various biological materials, leading to its renaming as the Biodiversity and Health Biobank - Fiocruz-BBS (Portuguese: Biobanco da Biodiversidade e Saúde da Fiocruz – BBS-Fiocruz). This paper outlines the challenges of creating and maintaining an adequate infrastructure in a developing country for promoting and supporting scientific research and biotechnological innovation activities in health through processes of depositing, characterizing, preserving, and supplying human and biodiversity biological materials, alongside associated data, while complying with prevailing legal and ethical rules. These processes adhere to stringent quality, biosafety, and biosecurity standards set forth in ISO 20387:2018. Additionally, the challenges of ensuring the Biobank’s long-term sustainability is discussed. This involves a) establishing benchmarks and best practices, b) developing a comprehensive business plan, c) forging partnerships, d) diversifying funding sources, e) ensuring ethical and legal compliance, f) implementing rigorous quality control procedures, and g) investing in human resources and infrastructure. The insights shared in this paper will benefit other biobanks engaged in services related to tropical infectious diseases.
- 26 June 2024
- Published by Frontiers Media SA in Frontiers in Tropical Diseases
- Vol. 5, 1420326
Open AccessChallenges of the new Fiocruz Biodiversity and Health Biobank for preparedness and response to emerging and re-emerging infectious diseases
During the COVID-19 pandemic, the Oswaldo Cruz Foundation (Fiocruz), a Brazilian federal research institution supported by the Brazilian Health Ministry, established a biobank. This biobank began by preserving the SARS-CoV-2 virus and human biological material related to COVID-19. This innovative initiative combined human and biodiversity materials within a single infrastructure. Designed for supporting research, development, and innovation in healthcare and preparedness and response to emerging and re-emerging infectious diseases, the biobank’s focus has since expanded to include various biological materials, leading to its renaming as the Biodiversity and Health Biobank - Fiocruz-BBS (Portuguese: Biobanco da Biodiversidade e Saúde da Fiocruz – BBS-Fiocruz). This paper outlines the challenges of creating and maintaining an adequate infrastructure in a developing country for promoting and supporting scientific research and biotechnological innovation activities in health through processes of depositing, characterizing, preserving, and supplying human and biodiversity biological materials, alongside associated data, while complying with prevailing legal and ethical rules. These processes adhere to stringent quality, biosafety, and biosecurity standards set forth in ISO 20387:2018. Additionally, the challenges of ensuring the Biobank’s long-term sustainability is discussed. This involves a) establishing benchmarks and best practices, b) developing a comprehensive business plan, c) forging partnerships, d) diversifying funding sources, e) ensuring ethical and legal compliance, f) implementing rigorous quality control procedures, and g) investing in human resources and infrastructure. The insights shared in this paper will benefit other biobanks engaged in services related to tropical infectious diseases.
- Open Access
Microbiological Collections in Brazil: Current Status and Perspectives
As part of a Ministry of Science, Technology, and Innovation initiative, the Brazilian Societies of Botany, Microbiology, Virology, and Zoology conducted a comprehensive evaluation of biological collections in Brazil. This assessment aimed to gather insights into the current state of these collections, with the goal of providing support for future public policies, including financial subsidies and prioritization policies. In this context, we present the findings related to microbiological collections, essential to ex situ biodiversity conservation and crucial in supporting research, development, and innovation. A survey was distributed to public and private institutions across Brazil, yielding responses from 168 microbiological collections representing 79 different entities. Notably, 73 of these collections are affiliated with public research institutions and universities, underscoring the State’s pivotal role in preserving and safeguarding Brazilian microbial diversity. The primary taxonomic groups encompass bacteria (found in 70.24% of collections) and fungi (comprising 52.98% of collections), sourced from diverse Brazilian ecosystems and biomes, including those that contain several type strains. Furthermore, the collections preserve microorganisms harboring biotechnological potential applicable to environmental protection, public health, industry, and agribusiness. Despite these promising economic and biotechnological prospects, our meticulous data analysis has revealed significant limitations and vulnerabilities, especially regarding physical infrastructure and human resources, emphasizing the urgent need for interventions to guarantee their sustainability.
Open AccessMicrobiological Collections in Brazil: Current Status and Perspectives
As part of a Ministry of Science, Technology, and Innovation initiative, the Brazilian Societies of Botany, Microbiology, Virology, and Zoology conducted a comprehensive evaluation of biological collections in Brazil. This assessment aimed to gather insights into the current state of these collections, with the goal of providing support for future public policies, including financial subsidies and prioritization policies. In this context, we present the findings related to microbiological collections, essential to ex situ biodiversity conservation and crucial in supporting research, development, and innovation. A survey was distributed to public and private institutions across Brazil, yielding responses from 168 microbiological collections representing 79 different entities. Notably, 73 of these collections are affiliated with public research institutions and universities, underscoring the State’s pivotal role in preserving and safeguarding Brazilian microbial diversity. The primary taxonomic groups encompass bacteria (found in 70.24% of collections) and fungi (comprising 52.98% of collections), sourced from diverse Brazilian ecosystems and biomes, including those that contain several type strains. Furthermore, the collections preserve microorganisms harboring biotechnological potential applicable to environmental protection, public health, industry, and agribusiness. Despite these promising economic and biotechnological prospects, our meticulous data analysis has revealed significant limitations and vulnerabilities, especially regarding physical infrastructure and human resources, emphasizing the urgent need for interventions to guarantee their sustainability.
- Open Access
- 7 December 2023
- Published by MDPI AG in Preprints.org
Microbiological Collections in Brazil: Current Status and Perspectives
As part of a project ordered by the Ministry of Science, Technology and Innovation of Brazil, an assessment of Brazilian biological collections was conducted by the Brazilian Societies of Botany, Microbiology, Virology and Zoology to obtain data on the current state of these collections. The goal was to provide subsidies for future public policies, including financial support and prioritization policies. Herein, we present the results of the microbiological collections, which play a fundamental role in the ex situ conservation of biodiversity and support research, development and innovation. A survey was sent to public and private institutions in Brazil and answered by 168 microbiological collections from 79 different institutions. Among these, 73 comprise public research institutions and universities, demonstrating the State's importance in preserving and safeguarding Brazilian microbial diversity. The main taxonomic groups are bacteria (present in 70.24% of the collections) and fungi (52.98% of the collections) from different Brazilian ecosystems and biomes, including several type strains. Furthermore, the collections preserve microorganisms with biotechnological potential for application in environmental protection, public health, industry, and agribusiness. However, despite all these economic and biotechnological potentials, the data analysis showed serious limitations and fragilities, especially regarding physical infrastructure and human resources, and raises alerts about the risk that Brazilian collections are subjected to.
- 7 December 2023
- Published by MDPI AG in Preprints.org
Open AccessMicrobiological Collections in Brazil: Current Status and Perspectives
As part of a project ordered by the Ministry of Science, Technology and Innovation of Brazil, an assessment of Brazilian biological collections was conducted by the Brazilian Societies of Botany, Microbiology, Virology and Zoology to obtain data on the current state of these collections. The goal was to provide subsidies for future public policies, including financial support and prioritization policies. Herein, we present the results of the microbiological collections, which play a fundamental role in the ex situ conservation of biodiversity and support research, development and innovation. A survey was sent to public and private institutions in Brazil and answered by 168 microbiological collections from 79 different institutions. Among these, 73 comprise public research institutions and universities, demonstrating the State's importance in preserving and safeguarding Brazilian microbial diversity. The main taxonomic groups are bacteria (present in 70.24% of the collections) and fungi (52.98% of the collections) from different Brazilian ecosystems and biomes, including several type strains. Furthermore, the collections preserve microorganisms with biotechnological potential for application in environmental protection, public health, industry, and agribusiness. However, despite all these economic and biotechnological potentials, the data analysis showed serious limitations and fragilities, especially regarding physical infrastructure and human resources, and raises alerts about the risk that Brazilian collections are subjected to.
- Open Access
- 23 February 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-5
Multilateral benefit-sharing from digital sequence information will support both science and biodiversity conservation
Open access to sequence data is a cornerstone of biology and biodiversity research, but has created tension under the United Nations Convention on Biological Diversity (CBD). Policy decisions could compromise research and development, unless a practical multilateral solution is implemented. Ensuring international benefit-sharing from sequence data without jeopardising open sharing is a major obstacle for the Convention on Biological Diversity and other UN negotiations. Here, the authors propose a solution to address the concerns of both developing countries and life scientists.
- 23 February 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-5
Open AccessMultilateral benefit-sharing from digital sequence information will support both science and biodiversity conservation
Open access to sequence data is a cornerstone of biology and biodiversity research, but has created tension under the United Nations Convention on Biological Diversity (CBD). Policy decisions could compromise research and development, unless a practical multilateral solution is implemented. Ensuring international benefit-sharing from sequence data without jeopardising open sharing is a major obstacle for the Convention on Biological Diversity and other UN negotiations. Here, the authors propose a solution to address the concerns of both developing countries and life scientists.
- Open Access
- 18 January 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (4)
Ethical, legal, and social issues in the Earth BioGenome Project
The Earth BioGenome Project (EBP) is an audacious endeavor to obtain whole-genome sequences of representatives from all eukaryotic species on Earth. In addition to the project’s technical and organizational challenges, it also faces complicated ethical, legal, and social issues. This paper, from members of the EBP’s Ethical, Legal, and Social Issues (ELSI) Committee, catalogs these ELSI concerns arising from EBP. These include legal issues, such as sample collection and permitting; the applicability of international treaties, such as the Convention on Biological Diversity and the Nagoya Protocol; intellectual property; sample accessioning; and biosecurity and ethical issues, such as sampling from the territories of Indigenous peoples and local communities, the protection of endangered species, and cross-border collections, among several others. We also comment on the intersection of digital sequence information and data rights. More broadly, this list of ethical, legal, and social issues for large-scale genomic sequencing projects may be useful in the consideration of ethical frameworks for future projects. While we do not—and cannot—provide simple, overarching solutions for all the issues raised here, we conclude our perspective by beginning to chart a path forward for EBP’s work.
- 18 January 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (4)
Open AccessEthical, legal, and social issues in the Earth BioGenome Project
The Earth BioGenome Project (EBP) is an audacious endeavor to obtain whole-genome sequences of representatives from all eukaryotic species on Earth. In addition to the project’s technical and organizational challenges, it also faces complicated ethical, legal, and social issues. This paper, from members of the EBP’s Ethical, Legal, and Social Issues (ELSI) Committee, catalogs these ELSI concerns arising from EBP. These include legal issues, such as sample collection and permitting; the applicability of international treaties, such as the Convention on Biological Diversity and the Nagoya Protocol; intellectual property; sample accessioning; and biosecurity and ethical issues, such as sampling from the territories of Indigenous peoples and local communities, the protection of endangered species, and cross-border collections, among several others. We also comment on the intersection of digital sequence information and data rights. More broadly, this list of ethical, legal, and social issues for large-scale genomic sequencing projects may be useful in the consideration of ethical frameworks for future projects. While we do not—and cannot—provide simple, overarching solutions for all the issues raised here, we conclude our perspective by beginning to chart a path forward for EBP’s work.
- Open Access
- 29 September 2020
- Published by Wiley in Plants, People, Planet
- Vol. 2 (5) , 546-556
Biodiversity and patents: Overview of plants and fungi covered by patents
Social Impact Statement: Patents can be used as a measure of innovation and to illustrate the commercial potential of plant and fungal biodiversity. The proportion of plant species named in patents represents only 6.2% of plant species, whereas the proportion of fungi is likely less than 0.4%. Fungi clearly justify further research. Innovation on a species usually drives more innovation on that species. We suggest that we should ensure that commercialization frameworks encourage studies on a greater diversity of plants and fungi. This could not only increase the range of biodiversity‐based products and associated income but also incentivize their conservation and encourage more fundamental research.Summary: In this review, patents are used as a measure of innovation, and data show that a low proportion of plant and fungal biodiversity is mentioned in patents. The proportion of plant species named in patents represents only 6.2% of plant species, whereas the proportion of fungi is most likely less than 0.4%. The number of species within a plant family mentioned in patents varies greatly. The following families having the greatest numbers: Asteraceae with 1,445 species (4.5% of species), Fabaceae with 1,299 species (5.8%), Poaceae with 1,008 species (8.5%), and Rosaceae with 718 species (12.7%). Case studies from Brazil, Ethiopia, and South Africa explore some of the controversies associated with patenting, especially when patents have not taken prior art into account. In contrast, a case study on plants and fungi used in traditional Chinese medicine illustrates their economic value and their potential to support new innovations. Innovative ways to use plant and fungal biodiversity has the potential to generate wealth, reduce poverty, improve human well‐being and in theory incentivize biodiversity conservation. International and national policies and laws that aim to facilitate equitable benefit‐sharing associated with access to and use of genetic diversity need to be reviewed to help facilitate innovation, as well as ensure that the rights of communities to use these resources are recognized and supported.
- 29 September 2020
- Published by Wiley in Plants, People, Planet
- Vol. 2 (5) , 546-556
Open AccessBiodiversity and patents: Overview of plants and fungi covered by patents
Social Impact Statement: Patents can be used as a measure of innovation and to illustrate the commercial potential of plant and fungal biodiversity. The proportion of plant species named in patents represents only 6.2% of plant species, whereas the proportion of fungi is likely less than 0.4%. Fungi clearly justify further research. Innovation on a species usually drives more innovation on that species. We suggest that we should ensure that commercialization frameworks encourage studies on a greater diversity of plants and fungi. This could not only increase the range of biodiversity‐based products and associated income but also incentivize their conservation and encourage more fundamental research.Summary: In this review, patents are used as a measure of innovation, and data show that a low proportion of plant and fungal biodiversity is mentioned in patents. The proportion of plant species named in patents represents only 6.2% of plant species, whereas the proportion of fungi is most likely less than 0.4%. The number of species within a plant family mentioned in patents varies greatly. The following families having the greatest numbers: Asteraceae with 1,445 species (4.5% of species), Fabaceae with 1,299 species (5.8%), Poaceae with 1,008 species (8.5%), and Rosaceae with 718 species (12.7%). Case studies from Brazil, Ethiopia, and South Africa explore some of the controversies associated with patenting, especially when patents have not taken prior art into account. In contrast, a case study on plants and fungi used in traditional Chinese medicine illustrates their economic value and their potential to support new innovations. Innovative ways to use plant and fungal biodiversity has the potential to generate wealth, reduce poverty, improve human well‐being and in theory incentivize biodiversity conservation. International and national policies and laws that aim to facilitate equitable benefit‐sharing associated with access to and use of genetic diversity need to be reviewed to help facilitate innovation, as well as ensure that the rights of communities to use these resources are recognized and supported.
- Open Access
- 24 June 2020
- Published by Pensoft Publishers in Biodiversity Data Journal
- Vol. 8, e53607
Fiocruz Biological Collections: strengthening Brazil's biodiversity knowledge and scientific applications opportunities
Biological collections are central in understanding and preserving life on Earth. In Brazil, the most representative collections are kept by natural history museums, whose primary focus is in invertebrates, vertebrates and vascular plants. Only a few institutions keep repositories in different kingdoms. The Oswaldo Cruz Foundation (Fiocruz), established in 1900, is a strategic public health institution of the Ministry of Health of Brazil. As such, Fiocruz is responsible for a wide range of activities, from basic research to the development and production of vaccines, drugs, reagents and diagnostic kits. Its biological collections were soon established in the expeditions made by naturalists and physicians seeking integrated knowledge of the fauna, flora and tropical diseases. Since then, they have been part of the institutional policy. In a few decades, those collections were already in the forefront of basic and applied research on tropical parasitic and infectious diseases. Currently, they comprise thirty-three repositories representing part of the Brazilian diversity of bacteria, fungi, protozoa, helminths, arthropods, molluscs and plants of medical and environmental importance. Different methods of long-term preservation are applied for the conservation of this wide range of organisms represented by about 6 million specimens. Herein, we describe this range of collections and discuss their complementary role as repositories of groups not represented in other biological collections in Brazil. These valuable biological materials have been used in public health and medical research, as well as for technological development and innovation in Brazil. Parallel to this specific usage, Fiocruz biological collections have played and continue to play a unique and important role in understanding and conserving part of Brazil’s biodiversity that is currently under-represented in other biological and natural history collections in Brazil and South America.
- 24 June 2020
- Published by Pensoft Publishers in Biodiversity Data Journal
- Vol. 8, e53607
Open AccessFiocruz Biological Collections: strengthening Brazil's biodiversity knowledge and scientific applications opportunities
Biological collections are central in understanding and preserving life on Earth. In Brazil, the most representative collections are kept by natural history museums, whose primary focus is in invertebrates, vertebrates and vascular plants. Only a few institutions keep repositories in different kingdoms. The Oswaldo Cruz Foundation (Fiocruz), established in 1900, is a strategic public health institution of the Ministry of Health of Brazil. As such, Fiocruz is responsible for a wide range of activities, from basic research to the development and production of vaccines, drugs, reagents and diagnostic kits. Its biological collections were soon established in the expeditions made by naturalists and physicians seeking integrated knowledge of the fauna, flora and tropical diseases. Since then, they have been part of the institutional policy. In a few decades, those collections were already in the forefront of basic and applied research on tropical parasitic and infectious diseases. Currently, they comprise thirty-three repositories representing part of the Brazilian diversity of bacteria, fungi, protozoa, helminths, arthropods, molluscs and plants of medical and environmental importance. Different methods of long-term preservation are applied for the conservation of this wide range of organisms represented by about 6 million specimens. Herein, we describe this range of collections and discuss their complementary role as repositories of groups not represented in other biological collections in Brazil. These valuable biological materials have been used in public health and medical research, as well as for technological development and innovation in Brazil. Parallel to this specific usage, Fiocruz biological collections have played and continue to play a unique and important role in understanding and conserving part of Brazil’s biodiversity that is currently under-represented in other biological and natural history collections in Brazil and South America.